1.
Bioorg Med Chem Lett
; 22(6): 2271-8, 2012 Mar 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-22342626
RESUMEN
Substituted azaquinazolinones were identified as antagonists of the GHSr-1A receptor for the treatment of type II diabetes and obesity. Optimisation for potency and LogD lead to the identification of orally bioavailable, potent antagonists with improved selectivity over hERG.